If beauty is in the eye of the beholder, Allergan's (AGN) earnings today were very pretty to some and not so pretty to others.
The maker of Botox and breast implants reported a higher-than-expected Q1 profit. But it also said earnings in Q2 would come in below Wall Street estimates.
While some analysts called it a strong report overall, investors were unnerved by the weak forecast. They bid shares down 3% from near an all-time high.
Allergan Chief Executive David Pyott joins the guys for this conversation.